West Pharmaceutical Services is a key player in the pharmaceutical industry, supplying proprietary packaging that almost every injectable drug needs. The company’s high-margin products are essential for GLP-1 weight loss drugs like Ozempic and Zepbound, as well as complex biologics, which are experiencing booming sales.
The company has rebounded strongly from a temporary inventory slowdown in 2024, with a pristine balance sheet and an experienced new CEO, Michel Lagarde, taking over in August.
As investors seek to benefit from the multiyear supercycle in GLP-1 drugs, West Pharmaceutical Services is a name many have discovered. They sit at the center of this ecosystem, supplying high-value components that enable these therapies to reach patients.
Patients turn to Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound, or even a generic to treat their obesity, and West’s products make all these injectable drugs possible. As GLP-1 use expands from diabetes and obesity into cardiovascular, kidney, liver, and other indications, the company’s sales will flourish.
Biologics market expansion and European Union regulatory upgrades are supporting recurring revenue and margin strength. West is also reshaping its portfolio for scale, having deepened its partnership with Daikyo Seiko and refocused its SmartDose platform on larger-volume systems, which will support the company as GLP-1 and biologics volumes ramp.
Related: ETF Investors Turn To Risk Assets Amid Uncertainty
Leadership continuity into this next phase is assured, with Michel Lagarde bringing a fresh, experienced hand to the company. Sales have already reaccelerated sharply since the 2024 inventory-led slowdown.
West’s second-quarter adjusted earnings per share jumped 29% from the prior year, and guidance was raised for the second time in 2026. Investors have already priced in some of this momentum, with West shares outperforming the market over the past year.
West shares currently trade at roughly 44x earnings, in line with its life sciences peers. The company functions as a critical backbone of modern medicine, designing and manufacturing elastomer stoppers and seals, prefillable syringe systems, and self-injection cartridges.
Because these products are consumable, every administered dose creates recurring revenue. West has two main segments: proprietary products and contract manufactured products.
The proprietary products division enjoys high margin growth, offering specialized proprietary packaging components, design services, and advanced administration systems. Contract manufacturing operates as a strategic partner to medical device and pharmaceutical companies.
Related: J&J shares dip despite strong earnings forecast
West’s operations are truly global, with a presence that is often adjacent to its customers. With a one-year return, the stock might look rich on most market-multiple checks.
However, the average analyst price target has risen along with its increased earnings estimates to sit at $397, implying 14% upside from here. The setup is less about being an undiscovered bargain and more about being a quality compounder priced for continued execution.
The catalysts – GLP-1 volume growth, biologics expansion, new CEO, portfolio reshaping – are real and identifiable, and the stock is well positioned to keep delivering.
West Pharmaceutical Services is well positioned.
